Ardelyx Receives New Patent for Tenapanor

Core Insights - Ardelyx, Inc. has been granted a new patent for IBSRELA and XPHOZAH, which will expire on November 26, 2042, covering the formulation of tenapanor [1][2] Company Overview - Ardelyx is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [1][15] - The company has two commercial products approved in the U.S.: IBSRELA and XPHOZAH [15] Product Information IBSRELA (tenapanor) - IBSRELA is an oral formulation that acts as a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), reducing sodium absorption and retaining luminal water content, which helps in softening stool consistency [3][11] - It has been shown to alleviate abdominal pain by decreasing visceral hypersensitivity and intestinal permeability in animal models [3] XPHOZAH (tenapanor) - XPHOZAH is a phosphate absorption inhibitor that works locally in the gut to reduce phosphate absorption through the paracellular pathway [4][14] - It is administered as a single tablet taken twice daily, with diarrhea being the most common side effect reported in clinical trials [4][13] Patent and Intellectual Property - The newly granted patent reflects a Patent Term Adjustment due to delays from the USPTO, extending protections for Ardelyx's portfolio of medicines [2] - The patent will be submitted for listing in the FDA's Orange Book for both IBSRELA and XPHOZAH [1]